Alexza's Corporate Presentation to be Webcast at the Eighth Annual JMP Securities...

Alexza's Corporate Presentation to be Webcast at the Eighth Annual JMP
Securities Research Conference

MOUNTAIN VIEW, Calif., May 11 /PRNewswire-FirstCall/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that its corporate
presentation will be webcast live during the Eighth Annual JMP Securities
Research Conference on Monday, May 18, 2009 at 3:30 p.m. Pacific Time. The
presentation will be webcast from The Ritz-Carlton Hotel in San Francisco, CA.

To access the live presentation via the Web, please go to the direct
conference link located at
http://www.wsw.com/webcast/jmp8/alxa or at the Alexza Investor Relations tab
at www.alexza.com.

A replay of the webcast will be made available approximately 24 hours after
the live presentation and the replay will be archived for 14 days.

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is a pharmaceutical company focused on the research,
development and commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. The Company's technology, the
Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol
that, when inhaled, allows for rapid systemic drug delivery through deep lung
inhalation. The drug is quickly absorbed through the lungs into the
bloodstream, providing speed of therapeutic onset that is comparable to
intravenous administration, but with greater ease, patient comfort and
convenience.

Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for
the acute treatment of agitation in schizophrenic or bipolar disorder
patients. Alexza has completed and announced positive results from both of
its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application
submission in early 2010.

The Company has completed an end-of-Phase 2 meeting with the FDA for AZ-001
(Staccato prochlorperazine) and it has advanced AZ-104 (Staccato loxapine)
into Phase 2b testing. Both product candidates are being developed for the
acute treatment of migraine headache. AZ-002 (Staccato alprazolam) has
completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial.
Product candidates that have completed Phase 1 testing are AZ-003 (Staccato
fentanyl) for the treatment of breakthrough pain and AZ-007 (Staccato
zaleplon) for the treatment of insomnia. More information, including this and
past press releases from Alexza, is available online at www.alexza.com.

Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that
involve significant risks and uncertainties. Any statement describing the
Company's expectations or beliefs is a forward-looking statement, as defined
in the Private Securities Litigation Reform Act of 1995, and should be
considered an at-risk statement. Such statements are subject to certain risks
and uncertainties, particularly those inherent in the process of developing
and commercializing drugs. The Company's forward-looking statements also
involve assumptions that, if they prove incorrect, would cause its results to
differ materially from those expressed or implied by such forward-looking
statements. These and other risks concerning Alexza's business are described
in additional detail in the Company's Annual Report on Form 10-K for the year
ended December 31, 2008, and the Company's other Periodic and Current Reports
filed with the Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and the Company
undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.

Thomas B. King, President & CEO, +1-650-944-7634, tking@alexza.com, or August
J. Moretti, Senior Vice President and CFO, +1-650-944-7788,
amoretti@alexza.com, both of Alexza Pharmaceuticals, Inc.